Quince Therapeutics, Inc.
General ticker "QNCX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $68.6M (TTM average)
Quince Therapeutics, Inc. follows the US Stock Market performance with the rate: 35.9%.
Estimated limits based on current volatility of 6.9%: low 3.35$, high 3.84$
Factors to consider:
- Total employees count: 32 (+52.4%) as of 2023
- Top business risk factors: Integration challenges, Limited operating history, Manufacturing risks, Regulatory and compliance, Market viability
- Current price 15.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.11$, 3.12$]
- 2025-12-31 to 2026-12-31 estimated range: [0.83$, 2.39$]
Financial Metrics affecting the QNCX estimates:
- Positive: with PPE of -2.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -40.82 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 28.03 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 18.93 < Shareholder equity ratio, % of 26.33 <= 41.86
Short-term QNCX quotes
Long-term QNCX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $52.02MM | $34.62MM | $57.28MM |
| Operating Income | $-52.02MM | $-34.62MM | $-57.28MM |
| Non-Operating Income | $0.07MM | $3.04MM | $0.54MM |
| R&D Expense | $25.18MM | $9.45MM | $18.59MM |
| Income(Loss) | $-51.94MM | $-31.58MM | $-56.74MM |
| Taxes | $-0.28MM | $-0.20MM | $0.09MM |
| Profit(Loss)* | $-51.66MM | $-31.39MM | $-56.83MM |
| Stockholders Equity | $100.59MM | $85.08MM | $30.15MM |
| Assets | $103.91MM | $167.90MM | $114.48MM |
| Operating Cash Flow | $-44.04MM | $-18.29MM | $-31.90MM |
| Capital expenditure | $0.13MM | $0.16MM | $0.26MM |
| Investing Cash Flow | $18.00MM | $-5.76MM | $21.91MM |
| Financing Cash Flow | $0.71MM | $0.14MM | $-4.78MM |
| Earnings Per Share** | $-1.54 | $-0.84 | $-1.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.